A naukri.com initiative
Bioengineer
6d
376
Image Credit: Bioengineer
Oncolytic Viruses Trigger Hyperacute Cancer Rejection
- Oncolytic viruses are being explored as a novel approach to induce hyperacute rejection against tumors, revolutionizing cancer therapy.
- This strategy aims to utilize viruses to trigger rapid and potent immune responses, leading to the destruction of cancer cells with exceptional speed and specificity.
- The approach involves manipulating the immune system through oncolytic viruses, which selectively infect and destroy cancer cells while sparing normal tissue.
- By inducing hyperacute rejection, researchers aim to mimic swift rejection mechanisms observed in organ transplantation immunology to achieve rapid tumor clearance.
- Engineering oncolytic viruses involves balancing viral replication, tumor specificity, and immunostimulatory capacity to provoke acute immune responses.
- The viral vectors serve as cytotoxic agents and immune stimulants, triggering complement activation, antibody-dependent cellular cytotoxicity, and recruitment of cytotoxic lymphocytes.
- Safety measures include tumor-selective promoters, localized viral administration, and safety switches to mitigate risks of normal tissue damage or off-target effects.
- Combining oncolytic viruses with immune checkpoint inhibitors or other therapies could enhance therapeutic outcomes by synergizing rapid tumor debulking with immune-based interventions.
- The induction of hyperacute rejection involves complex immune crosstalk, including the upregulation of pro-inflammatory signals and enhanced antigen presentation.
- Long-lasting anti-tumor immunity is essential for preventing cancer recurrence, with oncolytic viruses promoting the development of durable tumor-specific memory T cells and B cells.
Read Full Article
22 Likes
For uninterrupted reading, download the app